Breaking News Instant updates and real-time market news.

CTRV

ContraVir Pharmaceuticals

$1.12

-0.05 (-4.27%)

11:02
10/13/16
10/13
11:02
10/13/16
11:02

ContraVir jumps after reporting positive interim data for CMX157

ContraVir Pharmaceuticals reported positive interim data for CMX157, the Company's highly potent prodrug of tenofovir, from its ongoing Phase 2a multiple ascending dose clinical study. The head-to-head study is the first evaluation of CMX157 in HBV patients, and directly compares CMX157 to tenofovir disoproxil fumarate, TDF, Gilead's (GILD) Viread, in chronically infected hepatitis B, HBV, patients. Patients successfully completed both 5 mg and 10 mg cohorts, and interim data reported below are from 10 HBV-infected patients who completed 14 days of once-a-day oral dosing of 25 mg of CMX157, and two HBV patients treated for 14 days of oral dosing with 300 mg TDF. The CMX157 treated patients showed an average 99% reduction in HBV viral load compared to baseline. Significantly, the observed antiviral activity for CMX157 is comparable to that observed in TDF-treated patients, but at 1/12th the dose. A key goal of this study was to monitor levels of active tenofovir in the blood, exposure to which is a key predictor of off-target side effects. Following oral dosing, levels of CMX157 and active tenofovir in the bloodstream are approximately dose proportional and similar both in chronic HBV patients as well as in an earlier healthy volunteer study. Notably, CMX157 does not appear to break down readily into active tenofovir in the blood in contrast to patients taking Viread. The high levels of circulating tenofovir in subjects taking Viread are consistent with results from earlier published clinical studies of Viread in HIV and HBV patients. These results are significant considering that CMX157 achieved similar antiviral activity compared to Viread while significantly reducing systemic tenofovir exposure. Active tenofovir levels observed in blood following oral dosing of CMX157 are significantly below levels seen for Viread-treated patients, regardless of dose used, which is consistent with CMX157 targeting the liver followed by activation of CMX157 specifically within the liver. This is further supported by the observation that viral load reductions with CMX157 are comparable to Viread despite a significantly lower dose. "We are pleased and excited with these clinical results, as they demonstrate CMX157's great potential in our ongoing effort to develop a cure for HBV," said James Sapirstein, CEO of ContraVir. "The significant viral load reduction and favorable safety at this low dose of CMX157 speaks to the unique liver-targeting mechanism of our drug, which concentrates the antiviral activity of tenofovir in the liver, enabling anti-HBV efficacy at lower doses and minimal drug exposure to other tissues. We believe, based on the data that are being generated, that CMX157 has great potential as a safe and highly potent backbone of combination therapy against HBV." Pharmacokinetic data observed for CMX157 to date in healthy and HBV-infected subjects are similar across the completed Phase 1b and ongoing Phase 2a studies, consistent with the prodrug's site of action and anticipated improved safety profile. CMX157 was earlier found to be safe and well tolerated at daily oral doses of up to 100 mg in healthy volunteers and is presently demonstrating an excellent safety profile at 25 mg dose in the ongoing Phase 2a study in HBV patients. Upon completion of the 4-week dosing regimen and independent safety review, dose escalation is planned to continue at the 50 mg and 100 mg levels, respectively. Similarity of pharmacokinetic profiles observed for CMX157 in healthy and HBV-infected subjects strongly suggests that the remaining 50 mg and 100 mg doses of CMX157 in the ongoing Phase 2a study will also be safe and potentially even more active against HBV. Shares of ContraVir are up 21.44% or 24c to $1.36 per share in morning trading.

  • 01

    Nov

CTRV ContraVir Pharmaceuticals
$1.12

-0.05 (-4.27%)

05/06/16
MAXM
05/06/16
INITIATION
Target $4
MAXM
Buy
ContraVir Pharmaceuticals initiated with a Buy at Maxim
Target $4.

TODAY'S FREE FLY STORIES

07:50
04/26/17
04/26
07:50
04/26/17
07:50
General news
N.Y. FX Outlook »

N.Y. FX Outlook: The…

BDX

Becton Dickinson

$179.07

2 (1.13%)

, RHHBY

Roche

$32.41

0.397 (1.24%)

07:49
04/26/17
04/26
07:49
04/26/17
07:49
Hot Stocks
Becton Dickinson licenses novel molecular indexing technology to Roche »

Becton Dickinson (BDX)…

BDX

Becton Dickinson

$179.07

2 (1.13%)

RHHBY

Roche

$32.41

0.397 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 07

    May

  • 06

    Jun

  • 26

    Jun

HUM

Humana

$217.97

4.21 (1.97%)

07:49
04/26/17
04/26
07:49
04/26/17
07:49
Recommendations
Humana analyst commentary  »

Humana price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 16

    May

  • 13

    Jun

07:47
04/26/17
04/26
07:47
04/26/17
07:47
General news
Futures little changed as earnings parade marches on »

Stock futures are off…

CAT

Caterpillar

$104.42

7.61 (7.86%)

07:46
04/26/17
04/26
07:46
04/26/17
07:46
Recommendations
Caterpillar analyst commentary  »

Caterpillar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 14

    Jun

MCD

McDonald's

$141.70

7.47 (5.57%)

07:46
04/26/17
04/26
07:46
04/26/17
07:46
Recommendations
McDonald's analyst commentary  »

McDonald's price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SAP

SAP

$102.13

0.75 (0.74%)

07:45
04/26/17
04/26
07:45
04/26/17
07:45
Downgrade
SAP rating change  »

SAP downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

FCAU

Fiat Chrysler

$10.54

-0.02 (-0.19%)

07:44
04/26/17
04/26
07:44
04/26/17
07:44
Earnings
Fiat Chrysler confirms FY17 guidance for revenue, EBIT »

The Group confirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHI

Baker Hughes

$59.29

0.64 (1.09%)

07:43
04/26/17
04/26
07:43
04/26/17
07:43
Recommendations
Baker Hughes analyst commentary  »

Baker Hughes price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SYBT

S.Y. Bancorp

$42.30

0.85 (2.05%)

07:43
04/26/17
04/26
07:43
04/26/17
07:43
Earnings
S.Y. Bancorp reports Q1 EPS 47c, consensus 45c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 03

    May

CBOE

CBOE Holdings

$84.16

0.32 (0.38%)

07:43
04/26/17
04/26
07:43
04/26/17
07:43
Syndicate
CBOE Holdings 2.25M share Block Trade; price range $83.25-$83.75 »

Jefferies is acting as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

FCAU

Fiat Chrysler

$10.54

-0.02 (-0.19%)

07:43
04/26/17
04/26
07:43
04/26/17
07:43
Earnings
Fiat Chrysler reports Q1 adjusted EBIT EU1.54B, consensus EU1.44B »

Reports Q1 revenues of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSS

TSYS

$54.31

0.5 (0.93%)

07:42
04/26/17
04/26
07:42
04/26/17
07:42
Recommendations
TSYS analyst commentary  »

TSYS price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$19.45

-0.3083 (-1.56%)

07:42
04/26/17
04/26
07:42
04/26/17
07:42
Periodicals
Embraer partners with Uber to develop electric vehicles, Reuters reports »

Brazilian planemaker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLGN

Silgan Holdings

$60.10

0.24 (0.40%)

07:41
04/26/17
04/26
07:41
04/26/17
07:41
Earnings
Silgan Holdings raises FY17 adj. EPS view to $3.20-$3.40 from $3.15-$3.35 »

Silgan Holdings increased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

SAH

Sonic Automotive

07:41
04/26/17
04/26
07:41
04/26/17
07:41
Earnings
Sonic Automotive reports Q1 adjusted EPS 23c, consensus 23c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 20

    Jun

MMM

3M

07:40
04/26/17
04/26
07:40
04/26/17
07:40
Recommendations
3M analyst commentary  »

3M price target raised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 31

    May

07:40
04/26/17
04/26
07:40
04/26/17
07:40
General news
FX Update: The yen rebounded from fresh lows »

FX Update: The yen…

SLGN

Silgan Holdings

$60.10

0.24 (0.40%)

07:39
04/26/17
04/26
07:39
04/26/17
07:39
Earnings
Breaking Earnings news story on Silgan Holdings »

Silgan Holdings sees Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

IMAX

IMAX

07:39
04/26/17
04/26
07:39
04/26/17
07:39
Hot Stocks
IMAX and PVR Cinemas sign agreement for five theaters in India »

IMAX and PVR, the largest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEL

American Equity

$24.63

0.53 (2.20%)

07:38
04/26/17
04/26
07:38
04/26/17
07:38
Initiation
American Equity initiated  »

American Equity initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

EADSY

Airbus

$20.22

0.2 (1.00%)

07:38
04/26/17
04/26
07:38
04/26/17
07:38
Periodicals
China Southern to buy $6B in widebody jets from Airbus, Bloomberg reports »

China Southern Airlines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLGN

Silgan Holdings

$60.10

0.24 (0.40%)

07:38
04/26/17
04/26
07:38
04/26/17
07:38
Earnings
Silgan Holdings reports Q1 adj. EPS 62c, consensus 54c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

TROW

T. Rowe Price

$69.59

-3.04 (-4.19%)

07:38
04/26/17
04/26
07:38
04/26/17
07:38
Downgrade
T. Rowe Price rating change  »

T. Rowe Price downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

TOSBF

Toshiba, also use TOSYY

$1.96

0.024 (1.24%)

, TOSYY

Toshiba, also use TOSBF

$11.76

0.27 (2.35%)

07:38
04/26/17
04/26
07:38
04/26/17
07:38
Periodicals
Toshiba plans to replace auditor PwC, Reuters says »

Toshiba is planning to…

TOSBF

Toshiba, also use TOSYY

$1.96

0.024 (1.24%)

TOSYY

Toshiba, also use TOSBF

$11.76

0.27 (2.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.